Does Permanent Pacemaker Status Confer Mortality Benefit in the Short Term Post TAVI

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02700633

Enrollment

4000

Registered

2016-03-07

Start date

2016-02-29

Completion date

Unknown

Last updated

2016-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

TAVI

Brief summary

Pacemaker requirement in the immediate post procedure phase following TAVI is approximately 20% depending on device type and patient characteristics. There is a signal from recent studies suggesting increased risk of sudden cardiac / unexplained death in the first 30-60 days. This study aims to address whether there is a mortality advantage to having a pacemaker in the short term

Interventions

DEVICEPacemaker

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* All patients post TAVI

Exclusion criteria

* Nil

Design outcomes

Primary

Measure	Time frame
30 day mortality	30 dyas

Secondary

Measure	Time frame
60 day mortality	60 days

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026